Vera Therapeutics, Inc.
VERA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | – | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $1 | $1 | $0 | $0 |
| Gross Profit | -$1 | -$1 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $56 | $58 | $41 | $33 |
| G&A Expenses | $0 | $22 | $15 | $16 |
| SG&A Expenses | $27 | $22 | $16 | $16 |
| Sales & Mktg Exp. | $0 | $0 | $1 | $0 |
| Other Operating Expenses | $0 | -$0 | $0 | $0 |
| Operating Expenses | $83 | $80 | $57 | $49 |
| Operating Income | -$84 | -$80 | -$57 | -$49 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $4 | $4 | $6 | $5 |
| Pre-Tax Income | -$80 | -$77 | -$52 | -$43 |
| Tax Expense | – | $0 | $0 | $0 |
| Net Income | -$80 | -$77 | -$52 | -$43 |
| % Margin | – | – | – | – |
| EPS | -1.26 | -1.2 | -0.81 | -0.85 |
| % Growth | -5% | -48.1% | 4.7% | – |
| EPS Diluted | -1.26 | -1.2 | -0.81 | -0.85 |
| Weighted Avg Shares Out | 64 | 64 | 64 | 55 |
| Weighted Avg Shares Out Dil | 64 | 64 | 64 | 55 |
| Supplemental Information | – | – | – | – |
| Interest Income | $6 | $6 | $7 | $7 |
| Interest Expense | $2 | $2 | $2 | $2 |
| Depreciation & Amortization | $1 | $1 | $0 | $0 |
| EBITDA | -$78 | -$74 | -$50 | -$41 |
| % Margin | – | – | – | – |